hprt- Mutant T cells in the peripheral blood and synovial tissue of patients with rheumatoid arthritis

Arthritis and Rheumatism

Volumn 41, Issue 10, 1998, Pages 1772-1782

  Cannons, Jennifer Leigh ^a   Karsh, Jacob ^a   Birnboim, H Chaim ^a   Goldstein, Rose ^a  

^a UNIVERSITY OF OTTAWA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; FIBRONECTIN; FOLIC ACID; GOLD; HYDROXYCHLOROQUINE; HYPOXANTHINE PHOSPHORIBOSYLTRANSFERASE; INTEGRIN; METHOTREXATE; SALAZOSULFAPYRIDINE;

ARTICLE; CELL MUTANT; CONTROLLED STUDY; CORRELATION FUNCTION; FLOW CYTOMETRY; GENOTOXICITY; HUMAN; HUMAN CELL; LYMPHOCYTE CLONE; MAJOR CLINICAL STUDY; OSTEOARTHRITIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SYNOVIUM; T LYMPHOCYTE;

ADULT; AGED; ARTHRITIS, RHEUMATOID; CELL ADHESION; CELL LINE; CLONING, MOLECULAR; FEMALE; HUMANS; HYPOXANTHINE PHOSPHORIBOSYLTRANSFERASE; MALE; MIDDLE AGED; MUTATION; OSTEOARTHRITIS; SYNOVIAL MEMBRANE; T-LYMPHOCYTES;

EID: 0031691639     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/1529-0131(199810)41:10<1772::AID-ART9>3.0.CO;2-C     Document Type: Article

References (50)

1. Harris ED. Rheumatoid arthritis: pathophysiology and implications for therapy. N Engl J Med 1990;322;1227-89.
2. Panayi GS, Lanchbury JS, Kingsley GH. The importance of the T cell in initiating and maintaining the chronic synovitis of rheumatoid arthritis. Arthritis Rheum 1992;35:729-35.
3. Zvaifler NJ, Firestein GS. Pannus and pannocytes: alternative models of joint destruction in rheumatoid arthritis. Arthritis Rheum 1994;37:783-9.
4. Lindhlad S, Klareskog L, Hedfors E, Forsum U, Sundström C. Phenotypic characterization of synovial tissue cells in situ in different types of synovitis. Arthritis Rheum 1983;26:1321-32.
5. Goronzy JJ, Weyand CM. T cells in rheumatoid arthritis: paradigms and facts. Rheum Dis Clin North Am 1995;21:655-74.
6. Yeadon C, Karsh J. Lymphapheresis in rheumatoid arthritis: the clinical and laboratory effects of a limited course of cell depletion. Clin Exp Rheumatol 1983;1:119-24.
7. Landewé RBM, Goei Thé HS, van Rijthoven AWAM, Breedveld FC, Dijkmans BAC. A randomized, double-blind, 24-week controlled study of low-dose cyclosporine versus chloroquine for early rheumatoid arthritis. Arthritis Rheum 1994;37:637-43.
8. Kavanaugh AF, Davis LS, Nichols LA, Norris SH, Rothlein R, Scharschmidt LA, et al. Treatment of refractory rheumatoid arthritis with a monoclonal antibody to intercellular adhesion molecule 1. Arthritis Rheum 1994;37:992-9.
9. Rosen GM, Pou S, Ramos CL, Cohen MS, Britigan BE. Free radicals and phagocytic cells. FASEB J 1995;9:200-9.
10. Albertini RJ, Castle KL, Borcherding WR. T-cell cloning to detect the mutant 6-thioguanine-resistant lymphocytes present in human peripheral blood. Proc Natl Acad Sci U S A 1982;79:6617-21.
11. Morley AA, Trainor KJ, Seshadri R, Ryall RG. Measurement of in vivo mutations in human lymphocytes. Nature 1983;302:155-6.
12. Messing K, Bradley WEC. In vivo mutant frequency rises among breast cancer patients after exposure to high doses of irradiation. Mutat Res 1985;152:107-12.
13. Sala-Trepat M, Cole J, Green MHL, Rigaud O, Vilcoq JR, Moustacchi E. Genotoxic effects of radiotherapy and chemotherapy on the circulating lymphocytes of breast cancer patients. III. Measurement of mutant frequency to 6-thioguanine resistance. Mutagenesis 1990;5:593-8.
14. Cole J, Waugh APW, Beare DM, Sala-Trepat M, Stephens G, Green MHL. HPRT mutant frequencies in circulating lymphocytes: population studies using normal donors, exposed groups and cancer-prone syndromes. Prog Clin Biol Res 1991;372:319-28.
15. Gmelig-Meyling F, Dawisha S, Steinberg AD. Assessment of in vivo frequency of mutant T cells in patients with systemic lupus erythmatosus. J Exp Med 1992;175:297-300.
16. Dawisha SM, Gmelig-Meyling F, Steinberg AD. Assessment of clinical parameters associated with increased frequency of mutant T cells in patients with systemic lupus erythematosus. Arthritis Rheum 1994;37:270-7.
17. Sriram S. Longitudinal study of frequency of HPRT mutant T cells in patients with multiple sclerosis. Neurology 1994;44:311-5.
18. Sfikakis PP, Tesar J, Theocharis S, Klipple GL, Tsokos GC. Increased frequency on in vivo hprt gene-mutated T cells in the peripheral blood of patients with systemic sclerosis. Ann Rheum Dis 1993;53:122-7.
19. Cooper SM, Roessner KD, O'Neill JP, Budd RC, Albertini RJ. Increase in the fraction of mutant T cells in patients with rheumatoid arthritis [abstract]. Arthritis Rheum 1992;35 Suppl: R47.
20. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
21. Felson DT, Anderson JJ, Boers M, Bombardier C, Chernoff M, Fried B, et al. The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. Arthritis Rheum 1993;36:729-40.
22. Albertini RJ. Somatic gene mutations in vivo indicated by the 6-thioguanine-resistant T-lymphocytes in human blood. Mutat Res 1985;150:411-22.
23. Eichmann K, Falk I, Melchers I, Simon MM. Quantitative studies on T cell diversity: determination of precurser frequencies for two types of Streptococcal A-specific helper cells in non-immune, polyclonally activated splenic T cells. J Exp Med 1980;152:477-92.
24. St. John JT, Schroen DJ, Cheung TH. An adhesion assay using minimal shear force to remove nonadherent cells. J Immunol Methods 1994;170:159-66.
25. Hemler ME. VLA proteins in the integrin family: structures, functions, and their role on leukocytes. Annu Rev Immunol 1990;8:365-78.
26. Allegretta M, Nicklas JA, Sriram S, Albertini RJ. T cell responsive to myelin basic protein in patients with multiple sclerosis. Nature 1990;247:718-21.
27. Branda RF, Sullivan LM, O'Neill JP, Falta MT, Nicklas JA, Hirsch B, et al. Measurement of HPRt mutant frequencies in T-lymphocytes from healthy human populations. Mutat Res 1993; 285:267-79.
28. Liao H, Haynes BF. Role of adhesion molecules in the pathogenesis of rheumatoid arthritis. Rheum Dis Clin North Am 1995;21: 715-40.
29. Kerstens PJSM, Boerbooms AMT, Jeurissen MEC, Fast JH, Assmann KJM, van de Putte LBA. Accelerated nodulosis during low dose methotrexate therapy for rheumatoid arthritis: an analysis of ten cases. J Rheumatol 1992;19:867-71.
30. Albertini RJ, Nicklas JA, O'Neill PJ. Studies of DNA alterations in in vivo somatic cell mutations in humans. Basic Life Sci 1990;53: 315-28.
31. Connell WR, Kamm MA, Dickson M, Baikwill AM, Richie JK, Lennard-Jones JE. Long-term neoplastic risk after azathioprine treatment in inflammatory bowel disease. Lancet 1994;343:1249-52.
32. Van Dam FJ, Natarajan AT, Tates AD. Use of T-lymphocyte clonal assay for determining HPRT mutant frequencies in individual rats. Mutat Res 1992;271:231-42.
33. Hemler ME, Glass D, Coblyn JS, Jacobsen JG. Very late activation antigens on rheumatoid synovial fluid T lymphocytes: association with stages of T cell activation. J Clin Invest 1986;78:696-702.
34. Chan BMC, Elices MJ, Murphy E, Hemler ME. Adhesion to vascular cell adhesion molecule 1 and fibronectin: comparison of α4β1 (VLA-4) and α4β7 on the human B cell line JY. J Biol Chem 1992;267:8366-70.
35. FAK) in human T cells. J Exp Med 1995;182:2079-90.
36. Clark EA, Brugge JS. Integrins and signal transduction pathways: the road taken. Science 1995;268:233-9.
37. Rodriguez RM, Pitzalis C, Kingsley GH, Henderson MJ, Humpheries MJ, Panayi GS. T lymphocyte adhesion of fibronectin (FN): a possible mechanism for T cell accumulation in the rheumatoid joint. Clin Exp Immunol 1992;89:439-45.
38. Elices MJ, Tsai V, Strahl D, Goel SA, Tollefson V, Arrhenius T, et al. Expression and functional significance of alternatively spliced CS1 fibronectin in rheumatoid arthritis microvasculature. J Clin Invest 1994;93:405-16.
39. Lodge PA, Allegretta M, Steinman L, Sriram S. Myelin basic protein peptide specificity and T-cell receptor gene usage of hprt mutant T-cell clones in patients with multiple sclerosis. Ann Neurol 1994;36:734-40.
40. Theocharis S, Sfikakis PP, Lipnick RN, Klipple GL, Steinberg AD. Characterization of in vivo mutated T cell clones from patients with systemic lupus erythematosus. Clin Immunol Pathol 1995;74: 135-42.
41. Stuehr DJ, Griffith OW. Mammalian nitric oxide synthases. Adv Enzymol Relat Areas Mol Biol 1992;65:287-340.
42. Farrell AJ, Blake DR, Palmer RM, Moncada S. Increased concentrations of nitrite in synovial fluid and serum samples suggest increased nitric oxide synthesis in rheumatic disease. Ann Rheum Dis 1992;51:1219-22.
43. Grabowski PS, England AJ, Dykuizen R, Copland M, Benjamin N, Reid DM, et al. Elevated nitric oxide production in rheumatoid arthritis: detection using the fasting urinary nitrate:creatinine ratio. Arthritis Rheum 1996;39:643-7.
44. Heliovaara M, Knekt P, Aho K, Aaran RK, Alfthan G, Aromaa A. Serum antioxidants and risk of rheumatoid arthritis. Ann Rheum Dis 1994;53:51-3.
45. McCartney-Francis N, Allen JB, Mizel DE, Albina JE, Xie QW, Nathan CF, et al. Suppression of arthritis by an inhibitor of nitric oxide synthase. J Exp Med 1993;178:749-54.
46. Watson ML, Rao JK, Gilkeson GS, Ruiz P, Eicher EM, Pisetsky DS, et al. Genetic analysis of MRL-1pr mice: relationship of the Fas apoptosis gene to disease manifestations and renal disease-modifying loci. J Exp Med 1992;176:1645-56.
47. Firestein GS, Nguyen K, Aupperle KR, Yeo M, Boyle DL, Zvaifler NJ. Apoptosis in rheumatoid arthritis: p53 overexpression in rheumatoid arthritis synovium. Am J Pathol 1996;149:2143-51.
48. Gridley G, McLaughlin JK, Klareskog L, Adami HO, Hacker DG, Hoover R, et al. Incidence of cancer among patients with rheumatoid arthritis. J Natl Cancer Inst 1993;85:307-11.
49. McDuffie FC. Neoplasms in rheumatoid arthritis: update on clinical and epidemiologic data. Am J Med 1985;78 Suppl:1-83.
50. Laakso M, Mutru O, Isomaki H, Koota K. Cancer mortality in patients with rheumatoid arthritis. J Rheumatol 1986;13:522-6.